VRS Verisante Technology Inc

Verisante Technology, Inc. (TSX VENTURE:VRS) (OTCQX:VRSEF) (the "Company" or
"Verisante"), announced today that it has closed a non-brokered private
placement of 2,827,000 units ("Units") at a price of $0.17 per Unit for gross
proceeds of $480,590. Each Unit consists of one common share of the Company and
one common share purchase warrant (a "Warrant"). Each Warrant entitles the
holder to acquire a common share at a price of $0.25 for a period of 24 months
from the date of issuance, subject to certain acceleration provisions contained
within the warrant certificate. 


Among the strategic investors participating in this round of financing is
StarFish Medical, one of the Company's manufacturing partners for Aura(TM), a
medical device for the detection of skin cancer.


Thomas Braun, CEO, Verisante Technology, Inc., notes: "Our relationship with
StarFish Medical began with the Aura system. We're proud of how our teams worked
together to turn Verisante's original design concept into an award-winning
medical device. Our relationship continues to be strong, with StarFish Medical
manufacturing the Aura System for its expanding use in clinics." 


"Investing in a client company is a bit unique for us," said Scott Phillips,
President of StarFish Medical, "however our long relationship with Verisante
gives us insight and confidence in the company, product, and management team. We
feel this is a win-win opportunity." 


The private placement is subject to all necessary regulatory and stock exchange
approvals. Securities issued pursuant to the private placement are subject to a
hold period of four months plus one day from the date of distribution.


The net proceeds of the private placement will be used to fund the Company's
manufacturing of Aura(TM), to pursue additional regulatory approvals of Aura(TM)
in the United States and other regions, to support sales and marketing
initiatives, and for working capital requirements. 


A finder's fee of $8,160 cash and 48,000 finder's warrants was paid in
connection with this private placement.


About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative
systems for the early detection of cancer. The Verisante Aura(TM) for skin
cancer detection and the Verisante Core(TM) series for lung, colon and cervical
cancer detection utilize a proprietary cancer detection platform while the
operating software and probe technology are unique to each device. The cancer
detection platform was developed by the BC Cancer Agency and tested and refined
at the Skin Care Centre at Vancouver General Hospital. This exclusive platform
technology allows Verisante to develop and offer a range of compact,
non-invasive cancer detection devices that offer physicians immediate results
for many of the most common cancers. Aura(TM) has been approved for sale in
Canada, Europe and Australia. Core(TM) has not yet been approved for sale. 


Verisante Aura(TM) was awarded Popular Science Magazine's "Best of What's New
Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an
Edison Award for Excellence in Innovation in 2013. Verisante Core(TM) was named
one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. 


About StarFish Medical, Inc.

StarFish Medical is a Medical Device Design company offering a full range of
design, development, and manufacturing services. We use our Pathfinder(TM)
process to reduce wasted effort and increase success for innovative medical
device product definition, technical engineering, and product development.
Prototype and volume production are delivered in an ISO 13485 certified Quality
Management System and FDA registered manufacturing and clean room facility.


The TSX Venture Exchange has neither approved nor disapproved of the contents of
this press release. Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this press release. 


Forward Looking Statements 

This release contains forward-looking statements, including, but not limited to,
statements regarding the future commercialization of medical devices, the market
demand for these products and the proprietary protections the Company will
obtain with regard to the technology, all of which statements are subject to
market risks, and the possibility that the Company will not be able to obtain
patent protection or obtain sufficient customer demand. These statements are
made based upon current expectations and actual results may differ from those
projected due to a number of risks and uncertainties.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Verisante Technology, Inc.
Thomas Braun
President & CEO
(604) 605-0507
info@verisante.com
www.verisante.com


Youtube: www.youtube.com/verisante
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

Verisante Technology (TSXV:VRS)
Historical Stock Chart
From Nov 2024 to Dec 2024

Verisante Technology (TSXV:VRS)
Historical Stock Chart
From Dec 2023 to Dec 2024